Screening for cancer: Concepts and controversies

American Family Physician

Volumn 90, Issue 9, 2014, Pages 625-631

  Gates, Thomas J ^a  

^a LANCASTER GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COLONOSCOPY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; HUMAN; IMMUNOCHEMISTRY; LUNG CANCER; NEOPLASM; PROSTATE CANCER; RADIATION DOSE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SIGMOIDOSCOPY; TREATMENT OUTCOME; TUMOR GROWTH; AGED; CAUSE OF DEATH; CLASSIFICATION; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; EVIDENCE BASED PRACTICE; FEMALE; GENERAL PRACTICE; HEALTH SERVICE; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PROCEDURES; STANDARDS; STATISTICAL BIAS; SURVIVAL; TIME; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); CAUSE OF DEATH; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EVIDENCE-BASED PRACTICE; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MEDICAL OVERUSE; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 84908325382     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wallace RB. Screening for early and asymptomatic conditions. In: Maxcy KF, Rosenau MJ, Last JM, Wallace RB, eds. Maxcy-Rosenau-Last Public Health and Preventive Medicine. 14th ed. Stamford, Conn.: Appleton and Lange; 1998:907-908.
2. Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician. 2001;63(3):513-522.
3. Health maintenance and the role of screening. In: Goroll AH, Mulley AG, eds. Primary Care Medicine: Office Evaluation and Management of the Adult Patient. 5th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006:18.
4. Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343(22):1627-1633.
5. Sackett DL. Early diagnosis. In: Sackett DL, Haynes RB, Guyatt GH, Tugwell P, eds. Clinical Epidemiology: a Basic Science for Clinical Medicine. 2nd ed. Boston, Mass.: Little, Brown; 1991:153-170.
6. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published correction appears in CA Cancer J Clin. 2005;55(4):259]. CA Cancer J Clin. 2005;55(1):10-30.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
8. U.S. Preventive Services Task Force. Screening for cervical cancer: recommendation statement. Am Fam Physician. 2012;86(6):555-559.
9. Tria Tirona M. Breast cancer screening update. Am Fam Physician. 2013;87(4):274-278.
10. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149 (9):627-637.
11. American Academy of Family Physicians. Clinical preventive service recommendation. Colorectal cancer. http:// www.aafp.org/patient-care/clinical-recommendations/ all/colorectal-cancer.html. Accessed June 26, 2014.
12. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use- United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(44):881-888.
13. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;(1):CD001216 (updated online 2011).
14. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013; (9):CD009259.
15. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014;348:g2467.
16. Inadomi JM. Why you should care about screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25): 2421-2422.
17. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
18. Andriole GL, Crawford ED, Grubb RL III, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial [published correction appears in N Engl J Med. 2009;360(17):1797]. N Engl J Med. 2009;360(13):1310-1319.
19. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up [published correction appears in N Engl J Med. 2012; 366(22):2137]. N Engl J Med. 2012;366(11):981-990.
20. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;(1):CD004720.
21. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
22. American Academy of Family Physicians. Clinical preventive service recommendation. Prostate cancer. http:// www.aafp.org/patient-care/clinical-recommendations/ all/prostate-cancer.html. Accessed June 26, 2014.
23. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88-105.
24. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. April 2013. http://www. auanet.org/common/pdf/education/clinical-guidance/ Prostate-Cancer-Detection.pdf. Accessed December 27, 2013.
25. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med. 2011;365(21):2013-2019.
26. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.
27. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med. 2013;159(6):411-420.
28. Oken MM, Hocking WG, Kvale PA, et al.; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-1873.
29. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
30. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5): 330-338.
31. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369(3):245-254.
32. Patz EF Jr, Pinsky P, Gatsonis C, et al.; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer [published correction appears in JAMA Intern Med. 2014;174(5):828]. JAMA Intern Med. 2014;174(2):269-274.
33. American Academy of Family Physicians. Clinical preventive service recommendation. Lung cancer. http:// www.aafp.org/patient-care/clinical-recommendations/ all/lung-cancer.html. Accessed May 5, 2014.